Jones Financial Companies
BTAI

Jones Financial Companies’s BioXcel Therapeutics BTAI Stock Holding History

Jones Financial Companies’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$82.7K Sell
63,139
-68,650
-52% -$80.4K ﹤0.01% 2922
2026
Q1 		$166K Sell
131,789
-5,901
-4% -$9.72K ﹤0.01% 2463
2025
Q4 		$220K Buy
137,690
+101,690
+282% +$210K ﹤0.01% 1867
2025
Q3 		$97.2K Buy
36,000
+10,000
+38% +$31.5K ﹤0.01% 2103
2025
Q2 		$46K Buy
+26,000
New +$43K ﹤0.01% 2254

Other funds holding BTAI

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jones Financial Companies's BTAI Position: Q2 2026 in Review

Jones Financial Companies reduced its BioXcel Therapeutics (BTAI) stake by 52% in Q2 2026, selling an estimated $80.4K and leaving 63,139 shares worth $82.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2922.

Jones Financial Companies first reported a position in BTAI in Q2 2025 and has held it in 5 quarters since. The position peaked at $220K in Q4 2025. 47 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • Jones Financial Companies held 63,139 shares of BioXcel Therapeutics worth $82.7K as of Q2 2026.
  • Jones Financial Companies sold 68,650 BioXcel Therapeutics shares in Q2 2026, an estimated $80.4K.
  • BioXcel Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #2922 holding.
  • Jones Financial Companies first reported a position in BioXcel Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Jones Financial Companies's BioXcel Therapeutics position peaked at $220K in Q4 2025.
  • 47 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.